vs
Side-by-side financial comparison of TRANSACT TECHNOLOGIES INC (TACT) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.
Xilio Therapeutics, Inc. is the larger business by last-quarter revenue ($13.7M vs $11.5M, roughly 1.2× TRANSACT TECHNOLOGIES INC). TRANSACT TECHNOLOGIES INC produced more free cash flow last quarter ($589.0K vs $-2.1M).
Roper Technologies, Inc. is a holding company that owns companies in the technology sector.
Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.
TACT vs XLO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $11.5M | $13.7M |
| Net Profit | — | $10.4M |
| Gross Margin | 47.6% | — |
| Operating Margin | -10.1% | -86.5% |
| Net Margin | — | 75.7% |
| Revenue YoY | 11.9% | — |
| Net Profit YoY | — | 179.1% |
| EPS (diluted) | $-0.11 | $-3.74 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $11.5M | $13.7M | ||
| Q3 25 | $13.2M | $19.1M | ||
| Q2 25 | $13.8M | $8.1M | ||
| Q1 25 | $13.1M | $2.9M | ||
| Q4 24 | $10.2M | — | ||
| Q3 24 | $10.9M | — | ||
| Q2 24 | $11.6M | — | ||
| Q1 24 | $10.7M | — |
| Q4 25 | — | $10.4M | ||
| Q3 25 | $15.0K | $-16.3M | ||
| Q2 25 | $-143.0K | $-15.8M | ||
| Q1 25 | $19.0K | $-13.3M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-551.0K | — | ||
| Q2 24 | $-319.0K | — | ||
| Q1 24 | $-1.0M | — |
| Q4 25 | 47.6% | — | ||
| Q3 25 | 49.8% | — | ||
| Q2 25 | 48.2% | — | ||
| Q1 25 | 48.7% | — | ||
| Q4 24 | 44.2% | — | ||
| Q3 24 | 48.1% | — | ||
| Q2 24 | 52.7% | — | ||
| Q1 24 | 52.6% | — |
| Q4 25 | -10.1% | -86.5% | ||
| Q3 25 | 0.1% | -10.1% | ||
| Q2 25 | -1.9% | -177.7% | ||
| Q1 25 | -0.1% | -472.7% | ||
| Q4 24 | -10.3% | — | ||
| Q3 24 | -7.7% | — | ||
| Q2 24 | -3.8% | — | ||
| Q1 24 | -12.2% | — |
| Q4 25 | — | 75.7% | ||
| Q3 25 | 0.1% | -85.4% | ||
| Q2 25 | -1.0% | -196.0% | ||
| Q1 25 | 0.1% | -452.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -5.1% | — | ||
| Q2 24 | -2.8% | — | ||
| Q1 24 | -9.7% | — |
| Q4 25 | $-0.11 | $-3.74 | ||
| Q3 25 | $0.00 | $-0.11 | ||
| Q2 25 | $-0.01 | $-0.16 | ||
| Q1 25 | $0.00 | $-0.18 | ||
| Q4 24 | $-0.80 | — | ||
| Q3 24 | $-0.06 | — | ||
| Q2 24 | $-0.03 | — | ||
| Q1 24 | $-0.10 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $20.4M | $137.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $31.1M | $35.3M |
| Total Assets | $44.8M | $154.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $20.4M | $137.5M | ||
| Q3 25 | $20.0M | $103.8M | ||
| Q2 25 | $17.7M | $121.6M | ||
| Q1 25 | $14.2M | $89.1M | ||
| Q4 24 | $14.4M | — | ||
| Q3 24 | $11.3M | — | ||
| Q2 24 | $11.1M | — | ||
| Q1 24 | $10.6M | — |
| Q4 25 | $31.1M | $35.3M | ||
| Q3 25 | $31.8M | $-8.1M | ||
| Q2 25 | $31.3M | $7.1M | ||
| Q1 25 | $30.9M | $10.7M | ||
| Q4 24 | $30.6M | — | ||
| Q3 24 | $38.4M | — | ||
| Q2 24 | $38.5M | — | ||
| Q1 24 | $38.6M | — |
| Q4 25 | $44.8M | $154.7M | ||
| Q3 25 | $45.0M | $133.7M | ||
| Q2 25 | $44.5M | $133.8M | ||
| Q1 25 | $44.2M | $103.7M | ||
| Q4 24 | $44.0M | — | ||
| Q3 24 | $50.5M | — | ||
| Q2 24 | $50.4M | — | ||
| Q1 24 | $51.9M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $609.0K | $-2.0M |
| Free Cash FlowOCF − Capex | $589.0K | $-2.1M |
| FCF MarginFCF / Revenue | 5.1% | -15.3% |
| Capex IntensityCapex / Revenue | 0.2% | 0.7% |
| Cash ConversionOCF / Net Profit | — | -0.19× |
| TTM Free Cash FlowTrailing 4 quarters | $7.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $609.0K | $-2.0M | ||
| Q3 25 | $3.6M | $-17.5M | ||
| Q2 25 | $3.6M | $-14.5M | ||
| Q1 25 | $-161.0K | $29.0M | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $327.0K | — | ||
| Q2 24 | $636.0K | — | ||
| Q1 24 | $-1.5M | — |
| Q4 25 | $589.0K | $-2.1M | ||
| Q3 25 | $3.6M | — | ||
| Q2 25 | $3.6M | $-14.9M | ||
| Q1 25 | $-171.0K | $29.0M | ||
| Q4 24 | $2.4M | — | ||
| Q3 24 | $259.0K | — | ||
| Q2 24 | $499.0K | — | ||
| Q1 24 | $-1.6M | — |
| Q4 25 | 5.1% | -15.3% | ||
| Q3 25 | 27.1% | — | ||
| Q2 25 | 25.9% | -184.0% | ||
| Q1 25 | -1.3% | 988.3% | ||
| Q4 24 | 23.2% | — | ||
| Q3 24 | 2.4% | — | ||
| Q2 24 | 4.3% | — | ||
| Q1 24 | -14.9% | — |
| Q4 25 | 0.2% | 0.7% | ||
| Q3 25 | 0.5% | 0.0% | ||
| Q2 25 | 0.1% | 5.0% | ||
| Q1 25 | 0.1% | 0.8% | ||
| Q4 24 | 0.1% | — | ||
| Q3 24 | 0.6% | — | ||
| Q2 24 | 1.2% | — | ||
| Q1 24 | 1.0% | — |
| Q4 25 | — | -0.19× | ||
| Q3 25 | 242.00× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | -8.47× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
